These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 26809243

  • 21. Protective effect of epigallocatechin gallate on brain damage after transient middle cerebral artery occlusion in rats.
    Choi YB, Kim YI, Lee KS, Kim BS, Kim DJ.
    Brain Res; 2004 Sep 03; 1019(1-2):47-54. PubMed ID: 15306237
    [Abstract] [Full Text] [Related]

  • 22. Active immunization therapies for Parkinson's disease and multiple system atrophy.
    Schneeberger A, Tierney L, Mandler M.
    Mov Disord; 2016 Feb 03; 31(2):214-24. PubMed ID: 26260853
    [Abstract] [Full Text] [Related]

  • 23. Effects of dietary supplementation with epigallocatechin-3-gallate on weight loss, energy homeostasis, cardiometabolic risk factors and liver function in obese women: randomised, double-blind, placebo-controlled clinical trial.
    Mielgo-Ayuso J, Barrenechea L, Alcorta P, Larrarte E, Margareto J, Labayen I.
    Br J Nutr; 2014 Apr 14; 111(7):1263-71. PubMed ID: 24299662
    [Abstract] [Full Text] [Related]

  • 24. Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial.
    Chiaverini C, Roger C, Fontas E, Bourrat E, Bourdon-Lanoy E, Labrèze C, Mazereeuw J, Vabres P, Bodemer C, Lacour JP.
    Orphanet J Rare Dis; 2016 Mar 25; 11():31. PubMed ID: 27015660
    [Abstract] [Full Text] [Related]

  • 25. Epigallocatechin Gallate Extends the Therapeutic Window of Recombinant Tissue Plasminogen Activator Treatment in Ischemic Rats.
    You YP.
    J Stroke Cerebrovasc Dis; 2016 Apr 25; 25(4):990-7. PubMed ID: 26851971
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.
    Lancet Neurol; 2011 Mar 25; 10(3):230-40. PubMed ID: 21317042
    [Abstract] [Full Text] [Related]

  • 28. The European Multiple System Atrophy-Study Group (EMSA-SG).
    Geser F, Seppi K, Stampfer-Kountchev M, Köllensperger M, Diem A, Ndayisaba JP, Ostergaard K, Dupont E, Cardozo A, Tolosa E, Abele M, Dodel R, Klockgether T, Ghorayeb I, Yekhlef F, Tison F, Daniels C, Kopper F, Deuschl G, Coelho M, Ferreira J, Rosa MM, Sampaio C, Bozi M, Schrag A, Hooker J, Kim H, Scaravilli T, Mathias CJ, Fowler C, Wood N, Quinn N, Widner H, Nilsson CF, Lindvall O, Schimke N, Eggert KM, Oertel W, del Sorbo F, Carella F, Albanese A, Pellecchia MT, Barone P, Djaldetti R, Meco G, Colosimo C, Gonzalez-Mandly A, Berciano J, Gurevich T, Giladi N, Galitzky M, Ory F, Rascol O, Kamm C, Buerk K, Maass S, Gasser T, Poewe W, Wenning GK, EMSA-SG.
    J Neural Transm (Vienna); 2005 Dec 25; 112(12):1677-86. PubMed ID: 16049636
    [Abstract] [Full Text] [Related]

  • 29. (-)-Epigallocatechin-3-gallate (EGCG) modulates neurological function when intravenously infused in acute and, chronically injured spinal cord of adult rats.
    Renno WM, Al-Khaledi G, Mousa A, Karam SM, Abul H, Asfar S.
    Neuropharmacology; 2014 Feb 25; 77():100-19. PubMed ID: 24071567
    [Abstract] [Full Text] [Related]

  • 30. Nitric oxide pathway activity modulation alters the protective effects of (-)Epigallocatechin-3-gallate on reserpine-induced impairment in rats.
    Chen CN, Chang KC, Lin RF, Wang MH, Shih RL, Tseng HC, Soung HS, Tsai CC.
    Behav Brain Res; 2016 May 15; 305():198-211. PubMed ID: 26944334
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Decaffeinated green tea extract rich in epigallocatechin-3-gallate improves insulin resistance and metabolic profiles in normolipidic diet--but not high-fat diet-fed mice.
    Santana A, Santamarina A, Souza G, Mennitti L, Okuda M, Venancio D, Seelaender M, do Nascimento CO, Ribeiro E, Lira F, Oyama L.
    J Nutr Biochem; 2015 Sep 15; 26(9):893-902. PubMed ID: 26048201
    [Abstract] [Full Text] [Related]

  • 33. Parkinsonism in multiple system atrophy: natural history, severity (UPDRS-III), and disability assessment compared with Parkinson's disease.
    Tison F, Yekhlef F, Chrysostome V, Balestre E, Quinn NP, Poewe W, Wenning GK.
    Mov Disord; 2002 Jul 15; 17(4):701-9. PubMed ID: 12210859
    [Abstract] [Full Text] [Related]

  • 34. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice.
    Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, Tan J.
    Brain Res; 2008 Jun 12; 1214():177-87. PubMed ID: 18457818
    [Abstract] [Full Text] [Related]

  • 35. A-type dimeric epigallocatechin-3-gallate (EGCG) is a more potent inhibitor against the formation of insulin amyloid fibril than EGCG monomer.
    Nie RZ, Zhu W, Peng JM, Ge ZZ, Li CM.
    Biochimie; 2016 Jun 12; 125():204-12. PubMed ID: 27079519
    [Abstract] [Full Text] [Related]

  • 36. Neuroprotective Effect of a DJ-1 Based Peptide in a Toxin Induced Mouse Model of Multiple System Atrophy.
    Glat MJ, Ben-Zur T, Barhum Y, Offen D.
    PLoS One; 2016 Jun 12; 11(2):e0148170. PubMed ID: 26901405
    [Abstract] [Full Text] [Related]

  • 37. Therapeutic effects of EGCG: a patent review.
    Chakrawarti L, Agrawal R, Dang S, Gupta S, Gabrani R.
    Expert Opin Ther Pat; 2016 Aug 12; 26(8):907-16. PubMed ID: 27338088
    [Abstract] [Full Text] [Related]

  • 38. (-)-Epigallocatechin gallate as an intervention for the acute treatment of cerebral ischemia.
    Rahman RM, Nair SM, Helps SC, Shaw OM, Sims NR, Rosengren RJ, Appleton I.
    Neurosci Lett; 2005 Jul 15; 382(3):227-30. PubMed ID: 15925095
    [Abstract] [Full Text] [Related]

  • 39. Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice.
    Tipoe GL, Leung TM, Liong EC, Lau TY, Fung ML, Nanji AA.
    Toxicology; 2010 Jun 29; 273(1-3):45-52. PubMed ID: 20438794
    [Abstract] [Full Text] [Related]

  • 40. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG).
    Geser F, Wenning GK, Seppi K, Stampfer-Kountchev M, Scherfler C, Sawires M, Frick C, Ndayisaba JP, Ulmer H, Pellecchia MT, Barone P, Kim HT, Hooker J, Quinn NP, Cardozo A, Tolosa E, Abele M, Klockgether T, Østergaard K, Dupont E, Schimke N, Eggert KM, Oertel W, Djaldetti R, Poewe W, European MSA Study Group.
    Mov Disord; 2006 Feb 29; 21(2):179-86. PubMed ID: 16161136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.